Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Sun Pharmaceutical Industries reported a 36.2% profit fall in Q2 FY27 as net profit reached Rs 1,988.53 crore.
- ✓The company incurred Rs 346.16 crore in costs for the Organon acquisition.
- ✓While revenue rose 11.9% to Rs 16,198.71 crore, a Rs 922.67 crore US litigation settlement also impacted the firm’s quarterly earnings.
Story at a Glance
- Category
- BUSINESS
- Reported By
- The Economic Times
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Synopsis
Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.
Sun Pharmaceutical Industries incurred acquisition-related costs of Rs 346.16 crore in the September quarter as it continued preparations for its proposed acquisition of Organon & Co. The company reported a 36.2% year-on-year decline in consolidated net profit for the second quarter of FY27.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
The Economic Times
Read the full, original unfiltered story directly on the publisher's portal.